{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:25Z","timestamp":1793656525039,"version":"4.5.1"},"reference-count":21,"publisher":"American Society of Hematology","issue":"3","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,16]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>This study assessed real-world effectiveness and safety of lisocabtagene maraleucel (liso-cel) in patients with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL), including those with high-risk disease, secondary central nervous system (sCNS) involvement, comorbidities, and poor fitness, using data in the Center for International Blood and Marrow Transplant Research Registry from 5 February 2021 to 4 February 2025. Eligible patients (N = 1116) received liso-cel and had \u22651 effectiveness and safety assessment after infusion, including 195 in the second-line setting, 71 with sCNS, and 257 with transformed LBCL. Median age was 71.1 years (range, 21.5-91.2), with 72.3% aged \u226565 years. Within the overall population, 6.6% had an Eastern Cooperative Oncology Group performance status of \u22652, 53.4% had \u22651 comorbidity, and the median number of previous lines of therapy was 3 (range, 1-16). Median study follow-up was 12.6 months (95% confidence interval [CI], 12.5-12.8). Among effectiveness-evaluable patients (n = 1109), objective response rate was 81.2% and complete response rate was 71.3%. Duration of response, progression-free survival, and overall survival rates at 12 months were 60.2% (95% CI, 56.4-63.9), 51.2% (95% CI, 48.0-54.4), and 67.6% (95% CI, 64.5-70.6), respectively. Cytokine release syndrome was reported in 51.0% of patients, with grade \u22653 events in 2.5%. Immune effector cell\u2013associated neurotoxicity syndrome was reported in 26.6% of patients, with grade \u22653 events in 9.2%. The 12-month nonrelapse mortality rate was 6.1% (95% CI, 4.6-7.8). These real-world data reinforce the effectiveness and safety of liso-cel in this broad population of patients with R\/R LBCL, including younger patients and those with high-risk disease features.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031733","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:05:47Z","timestamp":1772557547000},"page":"348-360","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-5129","authenticated-orcid":false,"given":"Jennifer L.","family":"Crombie","sequence":"first","affiliation":[{"name":"1Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma\/Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[{"name":"3Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley D.","family":"Hunter","sequence":"additional","affiliation":[{"name":"4Intermountain LDS Hospital, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"5Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu-Sayeef","family":"Mirza","sequence":"additional","affiliation":[{"name":"6Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[{"name":"7Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogechukwu","family":"Egini","sequence":"additional","affiliation":[{"name":"8Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Silvina","family":"Odstrcil Bobillo","sequence":"additional","affiliation":[{"name":"9Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avyakta","family":"Kallam","sequence":"additional","affiliation":[{"name":"10Duarte Cancer Center, City of Hope Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"additional","affiliation":[{"name":"10Duarte Cancer Center, City of Hope Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasom C.","family":"Lee","sequence":"additional","affiliation":[{"name":"11Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[{"name":"11Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"12Blood and Marrow Transplant and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"10Duarte Cancer Center, City of Hope Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-8955","authenticated-orcid":false,"given":"Catherine J.","family":"Lee","sequence":"additional","affiliation":[{"name":"13Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krish","family":"Patel","sequence":"additional","affiliation":[{"name":"14Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-3615","authenticated-orcid":false,"given":"Sagar S.","family":"Patel","sequence":"additional","affiliation":[{"name":"15Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Reagan","sequence":"additional","affiliation":[{"name":"16University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"13Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"17Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-0575","authenticated-orcid":false,"given":"Soyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"18Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3364-0808","authenticated-orcid":false,"given":"Fei Fei","family":"Liu","sequence":"additional","affiliation":[{"name":"19Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasmita","family":"Roy","sequence":"additional","affiliation":[{"name":"19Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[{"name":"18Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Isufi","sequence":"additional","affiliation":[{"name":"20Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2026071611214694900_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/2278-330X.126531","article-title":"Management of relapsed-refractory diffuse large B cell lymphoma","volume":"3","author":"Raut","year":"2014","journal-title":"South Asian J Cancer"},{"issue":"1","key":"2026071611214694900_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2026071611214694900_bib3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"2026071611214694900_bib4","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/17474086.2016.1254547","article-title":"Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma","volume":"10","author":"Camus","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"14","key":"2026071611214694900_bib5","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026071611214694900_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"10254","key":"2026071611214694900_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"2026071611214694900_bib8","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"10532","key":"2026071611214694900_bib9","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(25)02435-3","article-title":"Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study","volume":"407","author":"Palomba","year":"2026","journal-title":"Lancet"},{"issue":"8","key":"2026071611214694900_bib10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10402","key":"2026071611214694900_bib11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"2026071611214694900_bib12","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026071611214694900_bib13","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1182\/bloodadvances.2021005292","article-title":"CAR T-cell therapy for secondary CNS DLBCL","volume":"5","author":"Ahmed","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2026071611214694900_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3324\/haematol.2022.281457","article-title":"Prevention and management of secondary central nervous system lymphoma","volume":"108","author":"Bobillo","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"2026071611214694900_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","article-title":"Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study","volume":"16","author":"Epperla","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2026071611214694900_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2026071611214694900_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"2026071611214694900_bib18","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"2026071611214694900_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","article-title":"Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma","volume":"93","author":"El-Galaly","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"2026071611214694900_bib20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","article-title":"Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis","volume":"9","author":"Riedell","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"2026071611214694900_bib21","first-page":"581.e1","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transpl Cell Ther"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/3\/348\/2533897\/blood_bld-2025-031733-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/3\/348\/2533897\/blood_bld-2025-031733-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:21:56Z","timestamp":1784215316000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/3\/348\/566908\/Real-world-outcomes-for-lisocabtagene-maraleucel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031733","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,16]]},"published":{"date-parts":[[2026,7,16]]}}}